XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
B
B

Biomarin

News

Reuters - 2 weeks ago

U.S. Celanese Corporation, Disc Medicine, Editas Medicine

U.S. RESEARCH ROUNDUP-Celanese Corporation, Disc Medicine, Editas Medicine Nov 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Celanese Corporation, Disc Medicine and Editas Medicine, on Tuesday. HIGHLIGHTS * Affiliated Managers Group Inc AMG.N : TD Cowen cuts to hold from buy * Celanese Corporation CE.N : Wells Fargo cuts to equal weight from overweight * Disc Medicine Inc IRON.O : Raymond James raises to strong b
A
A
B
C
C
E
H
I
M
V
W
E
F
B
C
Reuters - 3 weeks ago

U.S. Agilon Health, Alphabet, Crocs

U.S. RESEARCH ROUNDUP-Agilon Health, Alphabet, Crocs Oct 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agilon Health, Alphabet and Crocs, on Wednesday. HIGHLIGHTS * Agilon Health Inc AGL.N : Citigroup cuts to sell from neutral * Alphabet Inc GOOGL.O : Seaport Research Partners raises to buy from neutral * Crocs Inc CROX.O : Raymond James cuts to market perform from outperform * Leggett & Platt Inc LEG.N : Piper
A
B
C
G
I
M
Q
V
V
A
E
E
S
U
A
A
F
L
R
Reuters - 3 weeks ago

BioMarin Pharmaceutical Inc reports results for the quarter ended in January 1 - Earnings Summary

BioMarin Pharmaceutical Inc reports results for the quarter ended in January 1 - Earnings Summary BioMarin Pharmaceutical Inc BMRN.OQ reported quarterly adjusted earnings of 55 cents​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of 21 cents. The mean expectation of twenty eight analysts for the quarter was for earnings of 52 cents per share.
B
Reuters - 1 month ago

US FDA approves Pfizer's drug for rare bleeding disorder

UPDATE 2-US FDA approves Pfizer's drug for rare bleeding disorder Adds analyst estimates in paragraph 6, trial details in paragraph 8, and other treatments in paragraph 5, 10 and 11 By Sruthi Narasimha Chari and Christy Santhosh Oct 11 (Reuters) - The U.S. Food and Drug Administration approved Pfizer's PFE.N once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.
B
P
S
Reuters - 1 month ago

US FDA approves Pfizer's drug for rare bleeding disorder

US FDA approves Pfizer's drug for rare bleeding disorder Oct 11 (Reuters) - The U.S. Food and Drug Administration approved Pfizer's PFE.N once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday. Reporting by Sruthi Narasimha Chari and Christy Santhosh in Bengaluru; Editing by Vijay Kish
B
P
S
Reuters - 2 months ago

U.S. Constellation Brands, Ge Vernova, Republic Services

U.S. RESEARCH ROUNDUP-Constellation Brands, Ge Vernova, Republic Services Oct 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Brands, Ge Vernova and Republic Services, on Friday. HIGHLIGHTS * Constellation Brands Inc STZ.N : JP Morgan cuts target price to $293 from $307 * Diamondback Energy Inc FANG.O : Gerdes Energy Research cuts to neutral from buy * Ge Vernova GEV.N : HSBC cuts to hold from buy * R
B
P
G
L
R
Reuters - 2 months ago

Biomarin Pharmaceutical Inc Reaffirming Its Long-Term Financial Guidance And Outlook That It Presented During Investor Day

BRIEF-Biomarin Pharmaceutical Inc Reaffirming Its Long-Term Financial Guidance And Outlook That It Presented During Investor Day Sept 24 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : BIOMARIN PHARMACEUTICAL INC: REAFFIRMING ITS LONG-TERM FINANCIAL GUIDANCE AND OUTLOOK THAT IT PRESENTED DURING INVESTOR DAY Source text for Eikon: [ID:n0001193125-2
B
Reuters - 2 months ago

Ascendis Pharma slips after $300 mln share offering launch

BUZZ-Ascendis Pharma slips after $300 mln share offering launch ** U.S.-listed shares of Ascendis Pharma ASND.O down 4.3% at $142.50 in extended trading as co seeks equity raise ** Denmark-based biopharma announces $300 mln offering of American depositary shares (ADSs) ** JP Morgan, Morgan Stanley, Evercore and Goldman Sachs are jt bookrunners ** On Mon, ASND shares closed up ~17% at $139.57 after co said its achondroplasia therapy TransCon CNP met main goal in trial to treat dwarfism ** Shares
B
G
J
Reuters - 2 months ago

U.S. Aerovironment, Insulet, Viasat

U.S. RESEARCH ROUNDUP- Aerovironment, Insulet, Viasat Sept 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aerovironment, Insulet and Viasat, on Tuesday. HIGHLIGHTS * Aerovironment Inc AVAV.O : Raymond James cuts to market perform from outperform * Frontier Communications Parent Inc FYBR.O : JP Morgan cuts to neutral from overweight * Insulet Corp PODD.O : Piper Sandler raises target price to $285 from $230 * Relm
B
C
C
E
I
D
Reuters - 2 months ago

Ascendis rises on positive trial data for dwarfism therapy

BUZZ-Ascendis rises on positive trial data for dwarfism therapy ** U.S.-listed shares of Denmark-based Ascendis Pharma A71.F , ASND.O rise 17.3% to $139.88 ** ASND says its achondroplasia therapy TransCon CNP met its main goal by showing an average growth velocity of 5.89 cm/year vs 4.41 cm/year for a placebo in a trial ** Achondroplasia is a form
B
Reuters - 3 months ago

U.S. Coca-Cola, KB Home, Newmark Group

U.S. RESEARCH ROUNDUP-Coca-Cola, KB Home, Newmark Group Sept 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Coca-Cola, KB Home and Newmark Group on Thursday. HIGHLIGHTS * Capital Clean Energy Carriers CCEC.O : Evercore ISI initiates coverage with outperform rating * Coca-Cola Co KO.N : CFRA cuts to hold from buy * KB Home KBH.N : RBC cuts to underperform from sector perform * Newmark Group Inc NMRK.O : KBW raises
B
U
C
D
C
C
L
Reuters - 3 months ago

Biomarin Pharmaceutical Says On Aug 28, Entered Into Credit Agreement For Up To $600 Million In Revolving Loans

BRIEF-Biomarin Pharmaceutical Says On Aug 28, Entered Into Credit Agreement For Up To $600 Million In Revolving Loans Sept 4 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : BIOMARIN PHARMACEUTICAL: ON AUG 28, ENTERED INTO CREDIT AGREEMENT FOR UP TO $600 MILLION IN REVOLVING LOANS BIOMARIN PHARMACEUTICAL: CO WILL BE ENTITLED TO DRAW FUNDS AT ITS DI
B
Reuters - 3 months ago

Biomarin Holds Investor Day; Provides New Corporate Strategy And Introduces 2027 Financial Guidance

BRIEF-Biomarin Holds Investor Day; Provides New Corporate Strategy And Introduces 2027 Financial Guidance Sept 4 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : BIOMARIN HOLDS INVESTOR DAY; PROVIDES NEW CORPORATE STRATEGY AND INTRODUCES 2027 FINANCIAL GUIDANCE BIOMARIN PHARMACEUTICAL: SEES FY 2027 TOTAL REVENUES $4 BILLION BIOMARIN PHARMACEUTICAL:
B
Reuters - 3 months ago

BioMarin to reduce global workforce by about 225 employees

UPDATE 2-BioMarin to reduce global workforce by about 225 employees Adds job reduction details in paragraphs 4-6 Aug 28 (Reuters) - BioMarin Pharmaceutical BMRN.O w ill reduce its global workforce by about 225 employees, a filing showed on Wednesday. The decision comes in the wake of the company's updated strategy for its hemophilia gene therapy, Roctavian, and the discontinuation of its gene therapy BMN 293 development program.
B
Reuters - 3 months ago

BioMarin to reduce global workforce by about 225 employees

BioMarin to reduce global workforce by about 225 employees Aug 28 (Reuters) - BioMarin Pharmaceutical BMRN.O has decided to reduce its global workforce by about 225 employees, a filing showed on Wednesday. Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.